ARTHROTEC (diclofenac sodium and misoprostol) by Pfizer is sodium/misoprostol is a combination product containing diclofenac sodium, an nsaid with analgesic, anti-inflammatory and antipyretic properties, and misoprostol, a gi mucosal protective prostaglandin-1 (pge1) analog. Approved for prostaglandin e1 analog [epc], the signs, symptoms of osteoarthritis and 6 more indications. First approved in 1997.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
ARTHROTEC is a fixed-dose combination of diclofenac sodium (NSAID) and misoprostol (PGE1 analog) indicated for osteoarthritis and rheumatoid arthritis in patients at high risk for NSAID-induced gastric/duodenal ulcers. Diclofenac inhibits COX-1 and COX-2 to reduce pain and inflammation, while misoprostol protects the GI mucosa by increasing bicarbonate and mucus secretion.
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team restructuring and shift toward generic transition or repositioning strategies.
sodium/misoprostol is a combination product containing diclofenac sodium, an NSAID with analgesic, anti-inflammatory and antipyretic properties, and misoprostol, a GI mucosal protective prostaglandin-1 (PGE1) analog. Diclofenac The mechanism of action of diclofenac, like that of other NSAIDs, is…
Worked on ARTHROTEC at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Prostaglandin E1 Analog
ARTHROTEC offers limited career growth opportunities due to approaching LOE and declining competitive position; roles focus on managed-care, payer negotiation, and market-share defense rather than growth. Professionals joining should expect focus on cost optimization, generic transition planning, and potentially supporting portfolio re-allocation.